Our Sponsors

Pfizer Rare Disease merges pioneering science with a deep understanding of the underlying disease pathology to deliver innovative treatments. With over three decades of experience in rare disease, our broad global rare disease portfolio aims to address the unmet medical needs across a number of therapeutic areas, including haematology, neurology, endocrinology, cardiology, and inherited metabolic diseases.

For almost 100 years, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems, like our insulin pens.

Our treatments today are benefiting millions of people living with diabetes, obesity, and rare blood and endocrine diseases.

From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to patients throughout the world.

Our focus is on the serious chronic diseases that affect hundreds of millions of people and are among the most urgent global health challenges.

By combining our innovation and commercial excellence, we draw upon insights from patients and partners to transform bold ideas into life-saving and preventive medicines.

We make long-term investments in novel treatments and technologies, including curative stem cell-based therapies, to continually advance the development of medical devices and digital health solutions.

Who we are?

We are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark.

Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases.

We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat.

We employ more than 45.000 people in 80 offices around the world, and market our products in 169 countries.

At Sandoz our purpose is “Pioneering access for patients” through  the development of quality medicines which are priced fairly.   They can help more people and they free up resources for health

systems. Sandoz has a history of pioneering medical firsts and continue to develop complex generics and unlock the patents of biologics to create accessible biosimilars that can transform the lives of patients